<DOC>
	<DOCNO>NCT01531621</DOCNO>
	<brief_summary>- A population-based prospective study evaluate clinical behaviour , resectability survival 1st line metastatic colorectal cancer ( CRC ) patient Finland - Primary objective : To assess clinical behaviour metastatic colorectal cancer overall resectability , postoperative morbidity outcomes resection - Secondary objective : To assess treatment mCRC ; To assess efficacy chemotherapy target drug overall response rate ( ORR ) , failure free survival ( FFS ) , progression free survival ( PFS ) , overall survival ( OS ) ; To radiologically assess tumour density morphology , assess alternative radiologic response evaluation comparison RECIST response criterion ; To evaluate whole blood , plasma , serum tumour block biomarkers DNA polymorphism may predict drug effect , resectability clinical behaviour tumour</brief_summary>
	<brief_title>A Population-based Prospective Study Metastatic Colorectal Cancer ( CRC ) Patients Finland</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Patients histologically confirm CRC , schedule start get first line chemotherapy metastatic disease 2 . Age &gt; 18 3 . Metastatic disease ( include locally advanced disease amenable surgery and/or ( chemo ) radiotherapy ) 4 . Signed write informed consent accord ICH/GCP local regulation ( approved Independent Ethics Committee [ IEC ] ) obtain prior study 5 . No informed consent obtain patient participate data collection study obtain data hospital chart . No blood sampling , contact patient perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>